Navigation Links
OXiGENE Abstracts Published in ASCO Program

l M. Patterson of the Mount Vernon Cancer Centre indicates that while the study had not yet reached maximum tolerated dose and recruitment is ongoing, the data to date suggest that OXi4503 is tolerated at doses up to 5 mg/m2 without dose-limiting toxicity. Changes in functional activity, as assessed with DCI-MRI and PET imaging evaluations, were observed in three of the eleven patients studied. OXi4503 is a novel, second-generation vascular disrupting agent with potential intrinsic cytotoxicity exerted through an ortho-quinone metabolite. The drug candidate is being evaluated in this Phase I dose escalation and safety study. Based on results to date, OXiGENE currently anticipates initiating further clinical studies with OXi4503 in 2007.

About Combretastatin A4 Phosphate/CA4P (ZYBRESTAT) and OXi4503

ZYBRESTAT is poised to become the first therapeutic product in a novel class of small-molecule drug candidates called vascular disrupting agents (VDAs). The Company currently anticipates starting a Phase II/III pivotal registration study with ZYBRESTAT in June 2007 under a Special Protocol Assessment agreement with the US Food and Drug Administration. Via interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. ZYBRESTAT has demonstrated potent and selective activity against tumor vasculature, as well as substantial clinical activity against ATC and other solid tumors in clinical studies to date. Our strategy for optimizing the antitumor activity of ZYBRESTAT is to combine it with other types of therapeutic modalities, including cytotoxic drugs, anti-angiogenesis drugs, and radiation therapy. The rationale for combining ZYBRESTAT with other therapeutic modalities stems from the hypothesis that agents with different and potentially complimentary mechanisms of action and with a non-overlapping toxicity profile may achi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. OXiGENE Announces a Poster Presentation Highlighting Results from its Study of ZYBRETSTAT CA4P in Myopic Macular Degeneration (Study MMD-213) at the 47th Annual Meeting of the Association of Research in Vision and Ophthalmology
2. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
3. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
4. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
5. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
6. SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
9. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
10. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
11. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: OXiGENE Abstracts Published ASCO Program
(Date:12/16/2009)... HARTFORD, Conn., Dec. 16 CareCentrix, ... health benefits management services, announced today that it ... a Washington, DC-based health care accrediting organization that ... URAC standards guarantee that only appropriately trained, qualified ... process, that a reasonable and timely appeals process ...
(Date:12/16/2009)... Biovista Inc.,today announced that it was awarded the ... 2009 New England Venture Summit, held on December ... edge private companies,driving the future of innovation, was ... privately held companies that play a leading role ... sectors. , "We are ...
(Date:12/16/2009)... Dec. 16 GlaxoSmithKline plc [GSK] (NYSE: ... announced an exclusive licensing agreement in the United ... of NB-001, a novel, patented compound representing the ... Developed by NanoBio, NB-001 provides significant antimicrobial activity ... herpes labialis . ,, Cold sores are ...
Breaking Medicine Technology:CareCentrix Receives URAC Health Utilization Management Accreditation 2Biovista Inc. Named Top Innovator in Life Sciences 2GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment 2AACR NCI and EORTC to host Molecular Targets and Cancer Therapeutics International Conference 10655 1Retirement Brings Most a Big Health Boost 60954 1Retirement Brings Most a Big Health Boost 60954 2Retirement Brings Most a Big Health Boost 60954 3Natural Nutrition Acquires App Tech Global Inc 60952 1
... Pharmaceuticals today expanded its pipeline of products aimed ... agreement to license a new drug for the ... disorder, as well as other neurologic and psychiatric ... worldwide rights (excluding East Asia) to develop, manufacture ...
... The Epilepsy Foundation recently announced findings that show people ... consistent drug therapy, have a greater chance of increased ... medications are switched from one version of an antiepileptic ... generic-to-brand or generic-to-generic. See video from the Epilepsy Foundation ...
Other Medicine Technology:Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy 2Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy 3VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful 2
(Date:12/16/2009)... technology and the provider of the optimal paper-based e-data capture ... among the Fastest Growing Technology Companies on the Deloitte Technology ... ... (PRWEB) December 16, 2009 -- Kayentis provides ... of handwritten data. Kayentis targets the Healthcare and Life Sciences ...
(Date:12/16/2009)... government report shows, , , WEDNESDAY, Dec. 16 (HealthDay News) ... reached almost 78 years, a record high, federal health ... can expect to live to 80.4 years on average ... from the U.S. Centers for Disease Control and Prevention. ... live longer than their parents, life expectancy in the ...
(Date:12/16/2009)... Dec. 16 New research published ... compounds in pistachios, and molecules present in ... oil decreases levels of an inflammatory marker ... repeats 2). Inflammation is a complex biological ... or irritants, and it underlies functional changes ...
(Date:12/16/2009)... at the heart of diagnostic procedures in cardiology. The ... which accumulates the expertise of European cardiovascular imagers, is ... that it is written with a patient rather than ... the patient, with the aid of imaging. , ... themes involving theory and practice of cardiac imaging and ...
(Date:12/16/2009)... Satisfaction, New Partners and Global Market Expansion , ... ... provider of Feedback Analytics to Web sites and companies, today announced ... 25,000 new customers. Since its launch on July 2008, Kampyle ... 60 languages, and amassed more than 30,000 customers in 191 countries., ...
Breaking Medicine News(10 mins):Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 2Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 3Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 2Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 3Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 2Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 3Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 4Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 5
... that inflammation associated with the progression of tumors actually ... cancer. // ,The research identifies a mechanism, which ... late stages of prostate cancer development. The findings by ... of Gene Regulation and Signal Transduction, and colleagues may ...
... and Drug Administration (FDA) today approved Soliris (eculizumab), the ... (PNH), a rare type of blood disorder that can ... as an Orphan Drug and is a new molecular ... United States. ,"This product is important in ...
... prevention efforts are fueling the spread of HIV in Afghanistan, ... the Times, there are 69-recorded cases of HIV in the ... cases is much higher. The World Health Organization estimates that ... ,Nilufar Egamberdi, a World Bank consultant on HIV/AIDS, said the ...
... nursing home in southern Russia killed at least 63 persons on ... accident took place at a coastal village called Kamyshevatskaya. Emergency workers ... 1 a.m. It took them one hour to reach the village. ... 5 a.m., say officials. ,The incident comes less ...
... international study has come out strongly against the use of ... years. ,According to the Working Group on artificial ... Research on Cancer (IARC), persons who use these tanning beds ... up exposing themselves to higher risks of developing melanoma, the ...
... A new study claims that laughter brings out the humanitarian facet ... aid//. This research was conducted by Mark van Vugt and his ... were involved in this study were made to watch a hilarious ... While playing the game they were given money which they could ...
Other Medicine News:Health News:Inflammation May Play Role in Metastasis of Prostate Cancer 2Health News:Inflammation May Play Role in Metastasis of Prostate Cancer 3Health News:FDA Approves First-of-its-Kind Drug to Treat Rare Blood Disorder 2Health News:Stigma, Lack of Education, Prevent the Spread of HIV in Afghanistan 2
... King LT™ is a superior, disposable supraglottic ... advances in materials and design to provide ... LT™ emergency airway is a safe, reliable, ... emergency ventilation when direct laryngoscopy is not ...
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
... Available in even sizes 20-36F. Single use. ... patient comfort. The Latex-Free Robertazzi is the ... offering the best solution for latex sensitivity. ... offer a quality latex-free product as your ...
Bag of 9 airways 20-36 French (1234) or 4 airways 12-18 French (1233). Includes four foil packages of lubricating jelly....
Medicine Products: